Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-31T16:19:03.188Z Has data issue: false hasContentIssue false
  • English
  • Français

The Hla System and the Clinical Response to Treatment with Chlorpromazine

Published online by Cambridge University Press:  29 January 2018

E. Smeraldi ,
L. Bellodi ,
E. Sacchetti  and
C. L. Cazzullo
E. Smeraldi
Affiliation:
Biological Psychiatry Research Unit, Department of Psychiatry, Milan Medical School, Via F. Sforza, 35-20122 Milano, Italy
L. Bellodi
Affiliation:
Biological Psychiatry Research Unit, Department of Psychiatry, Milan Medical School, Via F. Sforza, 35-20122 Milano, Italy
E. Sacchetti
Affiliation:
Biological Psychiatry Research Unit, Department of Psychiatry, Milan Medical School, Via F. Sforza, 35-20122 Milano, Italy
C. L. Cazzullo
Affiliation:
Biological Psychiatry Research Unit, Department of Psychiatry, Milan Medical School, Via F. Sforza, 35-20122 Milano, Italy
Get access Rights & Permissions [Opens in a new window]

Summary

A group of 33 schizophrenic patients were typed for HLA-SD antigens and their qualitative clinical responses to chlorpromazine therapy determined. A highly significant positive correlation was found between response to chlorpromazine and HLA-A1 positive, while HLA-A2 positive subjects showed a significant negative correlation to chlorpromazine treatment.

In a second group of 17 patients the clinical responses to chlorpromazine were evaluated quantitatively, by WPRS, in HLA-A1 positive and HLA-A1 negative patients. There were no pre-treatment differences in the scores. After treatment the scores of positive patients were significantly lower, indicating that they responded to a greater degree.

Since the frequency of HLA-A1 in hebephrenic patients is higher than that in other schizophrenics this may explain our earlier finding that hebephrenics, as a group, respond better to chlorpromazine than do other schizophrenics.

Type
Papers
Information
The British Journal of Psychiatry , Volume 129 , Issue 5 , November 1976 , pp. 486 - 489
Copyright
Copyright © Royal College of Psychiatrists, 1976 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Castellano, C., Eleftheriou, B. E., Bailey, D. W. & oliverio, A. (1974) Chlorpromazine and avoidance a genetic analysis. Psychopharmacologia (Berl.), 34, 309—16.CrossRefGoogle ScholarPubMed
Cazzullo, C. L., Smeraldi, E. & Penati, G. (1974) The leucocyte antigenic system HLA-A1 as a possible genetic marker of schizophrenia. British Journal of Psychiatry, 125, 25—7.Google Scholar
Ferguson, R. M., Schmidtke, J. R. & Simmons, R. L. (1975) Concurrent inhibition by chlorpromazine of concanavalin a induced lymphocyte aggreation and mitogenesis. Nature, 256, 744—5.CrossRefGoogle Scholar
Fuller, J. L. (1970) Strain differences in the effects of chlorpromazine and chlordiazepoxide upon active and passive avoidance in mice. Psychopharmacologia (Berl.), 16, 261—71.Google Scholar
Hamill, W. T. & Fontana, A. F. (1975) The immediate effects of chlorpromazine in newly admitted schizophrenic patients. American Journal of Psychiatry, 132(10), 1023.Google Scholar
Kalow, W. (1966) Genetic aspects of drug safety. Applied Therapeutics, 8, 44—7.Google Scholar
Smeraldi, E., Bellodi, L. & Cazzullo, C. L. (1976) Further studies on the major histocompatibility complex (MHC) as a genetic marker for schizophrenia, Biological Psychiatry. In press.Google Scholar
Smeraldi, E. & Scorza-Smeraldi, R. (1976) Interference between anti-HLA antibodies and chlorpromazine. Nature, 260, 532—3.Google Scholar
Wittenborn, J. R. & Kiremitci, N. (1975) A comparison of antidepressant medications in neurotic and psychotic patients, Arch. Gen. Psychiat. 32, 1172—6.Google Scholar
World Health Organization (1970) Draft Glossary of Psychiatric Disorders. Geneva: WHO.Google Scholar
World Health Organization (1973) The International Pilot Study of Schizophrenia. Geneva: WHO, Vol 1.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.